Microbot Medical · 16 hours ago
Director, Health Economics and Outcomes Research (HEOR)
Microbot Medical is a cutting-edge medical device endovascular robotic surgery company, seeking an experienced, motivated, and enthusiastic Director of HEOR to join our team. The Director of HEOR will be responsible for developing and executing the global Health Economics and Outcome Research strategy to support market access, reimbursement, and adoption of the LIBERTY robotic system, generating real-world evidence, economic models, and value dossiers to demonstrate cost-effectiveness and healthcare system efficiency.
Medical Device
Responsibilities
Develop and implement a comprehensive Health Economics and Outcome Research strategy to support U.S. and global market access for the LIBERTY® Endovascular Robotic System
Translate clinical/usage data into health economics value messaging tailored for payers, providers, and policy makers which ultimately result in receiving a reimbursement code for LIBERTY
Provide input in the design of real-world evidence (RWE) registries and post-market studies to demonstrate economic impact
Lead development of health economic models (budget impact, cost-effectiveness, resource utilization) to support the commercial organization
Establish strong market awareness by publishing Health Economics and Outcome Research findings in peer-reviewed journals and present at major scientific and economic conferences
Partner with vendors and Marketing, Sales, and Clinical Affairs colleagues to develop payer dossiers, value briefs, and HTA submissions
Lead coding, coverage, and payment strategies with data-driven evidence
Collaborate with Sales team members to engage hospital Value Analysis Committees with robust clinical and economic evidence
Build strong relationships with key opinion leaders, payers, policy makers, and hospital administrators
Educate and support external stakeholders on procedures coding and reimbursement best practices
Establish and manage Health Economics and Outcome Research advisory boards
Provide Health Economics and Outcome Research insights to marketing, sales, and clinical teams to strengthen the value story in commercialization
Educate internal and external stakeholders on evidence-based value messaging
Travel to and attend relevant industry conferences and trade shows, which may take place during weekends and holidays
Attend company dinners and events as needed
Meet the travel requirements of the position as outlined below
Perform other duties as assigned by the Company
Qualification
Required
Advanced degree in health economics, outcomes research, epidemiology, public health, pharmacy, or related discipline (PhD, PharmD, MPH, or MS preferred)
10+ years of progressive Health Economics and Outcome Research experience in medical devices, with direct payer-facing experience
Strong track record in designing and executing economic models and RWE studies
Experience supporting product launch and commercialization of innovative medical technologies
Deep understanding and experience in U.S. reimbursement processes (coding, coverage, payment) and global HTA requirements. Understanding and experience in reimbursement processes in Europe and Asia Pacific a plus
Demonstrated ability to communicate complex data to diverse internal and external stakeholders, including payers, providers, and cross functional teams
Excellent leadership, communication, and collaboration skills
Strong analytical and problem-solving skills
Ability to work independently and as part of a team
Proficient in statistical software and data analysis tools
Experience in the medical device industry
Preferred
Familiarity with health policy and regulatory environments
Benefits
Competitive salary and benefits package.
Company
Microbot Medical
Microbot Medical is the first medical device company specialized in the researching, designing, developing and commercializing.
Funding
Current Stage
Public CompanyTotal Funding
$153.54MKey Investors
Israel Innovation Authority
2025-09-15Post Ipo Equity· $92.2M
2025-08-05Grant· $0.63M
2025-02-10Post Ipo Equity· $13M
Recent News
2026-01-12
Company data provided by crunchbase